Usefulness of competitive inhibitors of protein binding for improving the pharmacokinetics of 186Re-MAG3-conjugated bisphosphonate ( 186Re-MAG3-HBP), an agent for treatment of painful bone metastases

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 36, Issue 1, 2009, Pages 115-121

  Ogawa, Kazuma ^a,b   Mukai, Takahiro ^a,c   Kawai, Keiichi ^b,d   Takamura, Norito ^e   Hanaoka, Hirofumi ^a   Hashimoto, Kazuyuki ^f   Shiba, Kazuhiro ^b   Mori, Hirofumi ^b   Saji, Hideo ^a  

^a KYOTO UNIVERSITY   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

^d UNIVERSITY OF FUKUI   (Japan)

^e KYUSHU UNIVERSITY OF HEALTH AND WELFARE   (Japan)

^f JAPAN ATOMIC ENERGY AGENCY   (Japan)

Author keywords

186Re; Absorbed radiation dose; Bisphosphonate; Palliation; Protein binding

Indexed keywords

BISPHOSPHONATE MERCAPTOACETYLGLYCYLGLYCYLGLYCINE RE 186 CONJUGATE; BISPHOSPHONIC ACID DERIVATIVE; BUCOLOME; CEFAZOLIN; CEFTRIAXONE; HUMAN SERUM ALBUMIN; IBUPROFEN; MERTIATIDE TC 99M; PLASMA PROTEIN; RHENIUM 186; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; BINDING SITE; BLOOD VOLUME; BONE METASTASIS; BONE PAIN; COMPETITIVE INHIBITION; CONTROLLED STUDY; DOSIMETRY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG TISSUE LEVEL; MALE; NONHUMAN; PROTEIN BINDING; RADIOACTIVITY; RAT; SERUM; TISSUE DISTRIBUTION;

ANIMALS; BINDING, COMPETITIVE; BONE NEOPLASMS; DIPHOSPHONATES; HUMANS; MALE; ORGANOMETALLIC COMPOUNDS; PAIN; PROTEIN BINDING; RADIOMETRY; RATS; RATS, WISTAR; REPRODUCIBILITY OF RESULTS; SERUM ALBUMIN; TISSUE DISTRIBUTION;

EID: 57249084283     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-008-0925-8     Document Type: Article

References (34)

1. DR Clohisy PW Mantyh 2003 Bone cancer pain Cancer 97 866 873
2. VJ Lewington 2005 Bone-seeking radionuclides for therapy J Nucl Med 46 Suppl 1 38S 47S
3. K Ogawa T Mukai Y Arano M Ono H Hanaoka S Ishino 2005 Development of a rhenium-186-labeled MAG3-conjugated bisphosphonate for the palliation of metastatic bone pain based on the concept of bifunctional radiopharmaceuticals Bioconjug Chem 16 751 757
4. K Ogawa T Mukai Y Arano H Hanaoka K Hashimoto H Nishimura 2004 Design of a radiopharmaceutical for the palliation of painful bone metastases: rhenium-186-labeled bisphosphonate derivative J Labelled Cmpd Radiopharm 47 753 761
5. K Ogawa T Mukai Y Arano A Otaka M Ueda T Uehara 2006 Rhenium-186- monoaminemonoamidedithiols conjugated bisphosphonate derivatives for bone pain palliation Nucl Med Biol 33 513 520
6. 186Re-complex-conjugated bisphosphonate for the palliation of metastatic bone pain in an animal model J Nucl Med 48 122 127
7. 186Re chelate-conjugated bisphosphonate for the development of new radiopharmaceuticals for bones Nucl Med Biol 34 79 87
8. AM Verbruggen DL Nosco CG Van Nerom GM Bormans PJ Adriaens MJ De Roo 1992 Technetium-99m-L,L-ethylenedicysteine: a renal imaging agent. I. Labeling and evaluation in animals J Nucl Med 33 551 557
9. A Taylor Jr. D Eshima PE Christian WW Wooten L Hansen K McElvany 1988 Technetium-99m MAG3 kit formulation: preliminary results in normal volunteers and patients with renal failure J Nucl Med 29 616 622
10. 99mTc-labeled tubular agents J Nucl Med 41 2077 2082
11. 99mTc-chelate-conjugated bisphosphonate with high affinity for bone as a bone scintigraphic agent J Nucl Med 47 2042 2047
12. G Sudlow DJ Birkett DN Wade 1975 The characterization of two specific drug binding sites on human serum albumin Mol Pharmacol 11 824 832
13. G Sudlow DJ Birkett DN Wade 1976 Further characterization of specific drug binding sites on human serum albumin Mol Pharmacol 12 1052 1061
14. N Takamura A Haruta H Kodama M Tsuruoka K Yamasaki A Suenaga 1996 Mode of interaction of loop diuretics with human serum albumin and characterization of binding site Pharm Res 13 1015 1019
15. N Takamura T Maruyama S Ahmed A Suenaga M Otagiri 1997 Interactions of aldosterone antagonist diuretics with human serum proteins Pharm Res 14 522 526
16. N Takamura T Maruyama M Otagiri 1997 Effects of uremic toxins and fatty acids on serum protein binding of furosemide: possible mechanism of the binding defect in uremia Clin Chem 43 2274 2280
17. U Kragh-Hansen VT Chuang M Otagiri 2002 Practical aspects of the ligand-binding and enzymatic properties of human serum albumin Biol Pharm Bull 25 695 704
18. 99mTc-MAG3 serum protein binding in in-vitro and in-vivo J Label Cmpd Radiopharm 42 S584 S586
19. 188Re generator Radiochemistry 42 551 554
20. H Abe M Sawada T Toda N Kurosawa E Owada I Tazawa 1995 Evaluation of co-administration of bucolome for warfarin therapy from the view point of protein binding Jpn J Ther Drug Monit 12 293 298
21. N Takamura T Maruyama E Chosa K Kawai Y Tsutsumi Y Uryu 2005 Bucolome, a potent binding inhibitor for furosemide, alters the pharmacokinetics and diuretic effect of furosemide: potential for use of bucolome to restore diuretic response in nephrotic syndrome Drug Metab Dispos 33 596 602
22. PJ McNamara V Trueb K Stoeckel 1990 Ceftriaxone binding to human serum albumin. Indirect displacement by probenecid and diazepam Biochem Pharmacol 40 1247 1253
23. MO Decroix R Zini JC Chaumeil JP Tillement 1988 Cefazolin serum protein binding and its inhibition by bilirubin, fatty acids and other drugs Biochem Pharmacol 37 2807 2814
24. K Yamaoka T Nakagawa T Uno 1978 Statistical moments in pharmacokinetics J Pharmacokinet Biopharm 6 547 558
25. JM de Klerk EB van Dieren AD van het Schip A Hoekstra BA Zonnenberg A van Dijk 1996 Bone marrow absorbed dose of rhenium-186-HEDP and the relationship with decreased platelet counts J Nucl Med 37 38 41
26. HB Lee MD Blaufox 1985 Blood volume in the rat J Nucl Med 26 72 76
27. M Neves L Gano N Pereira MC Costa MR Costa M Chandia 2002 Synthesis, characterization and biodistribution of bisphosphonates Sm-153 complexes: correlation with molecular modeling interaction studies Nucl Med Biol 29 329 338
28. 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases J Nucl Med 44 953 960
29. MG Stabin RB Sparks E Crowe 2005 OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine J Nucl Med 46 1023 1027
30. T Haradahira M Zhang J Maeda T Okauchi K Kawabe T Kida 2000 A strategy for increasing the brain uptake of a radioligand in animals: use of a drug that inhibits plasma protein binding Nucl Med Biol 27 357 360
31. IH Patel S Chen M Parsonnet MR Hackman MA Brooks J Konikoff 1981 Pharmacokinetics of ceftriaxone in humans Antimicrob Agents Chemother 20 634 641
32. M Seddon R Wise AP Gillett R Livingston 1980 Pharmacokinetics of Ro 13-9904, a broad-spectrum cephalosporin Antimicrob Agents Chemother 18 240 242
33. JM O'Sullivan VR McCready G Flux AR Norman FM Buffa S Chittenden 2002 High activity Rhenium-186 HEDP with autologous peripheral blood stem cell rescue: a phase I study in progressive hormone refractory prostate cancer metastatic to bone Br J Cancer 86 1715 1720
34. 186Re-HEDP with autologous peripheral blood stem cell transplant in progressive hormone-refractory prostate cancer metastatic to bone Eur J Nucl Med Mol Imaging 33 1055 1061